Introduction {#Sec1}
============

Stroke is the second leading cause of disability in Europe after ischaemic heart disease and the sixth leading cause worldwide^[@CR1]^. In Europe, the annual cost of stroke is an estimated €27 billion: €18.5 billion for direct costs and €8.5 billion for indirect costs^[@CR2]^.

Carotid atherosclerosis is a significant cause of ischemic stroke and transient ischemic attack (TIA)^[@CR3],[@CR4]^. The optimal treatment for patients with asymptomatic carotid disease remains controversial with no clear consensus to recommend the best therapy for them. Carotid endarterectomy (CEA) has been suggested to be superior in preventing stroke compared to medical therapy alone in asymptomatic patients with \>70% stenosis^[@CR5]^. Carotid stenting (CAS) has emerged as a therapeutic alternative to endarterectomy for the treatment of severe carotid stenosis. The results of randomized trials comparing stenting and endarterectomy have been conflicting^[@CR6],[@CR7]^.

In 2011, the American Heart Association (AHA) published its updated guidelines on the role of CEA and CAS in asymptomatic patients^[@CR8]^. Its recommendations were based on two landmarks randomised clinical trials published in 1995 and 2004^[@CR9],[@CR10]^. However, medical therapy in these trials was not comparable with current standards. Medical therapy for stroke prevention has improved since these original trials, with more widespread use of statins, more active lowering of blood pressure and more effective antiplatelet regimes. More recent data from the Oxford Vascular Study (OXVASC) demonstrate a stroke risk of only 0.3% per year attributable to ipsilateral asymptomatic carotid stenosis treated with best medical therapy (BMT) alone^[@CR11]^.

In view of the improving medical therapy for stroke prevention with more widespread use of statins, more active lowering of blood pressure and more effective antiplatelet regimes, there is currently uncertainty as to whether carotid intervention (endarterectomy or stenting) provides clinical benefits and superior outcomes over optimised medical therapy in patient cohorts with asymptomatic carotid disease. Our systematic review investigated outcomes of treatment strategies for asymptomatic carotid disease applying network meta-analytic techniques.

Results {#Sec2}
=======

Literature search results {#Sec3}
-------------------------

The initial literature search identified a total of 523 records. Two additional relevant records were identified through manual search of the references lists. Out of the 525 articles 23 articles were relevant to this study and the full-texts were assessed for eligibility criteria. Eleven articles^[@CR9],[@CR10],[@CR12]--[@CR20]^ met the inclusion criteria and were incorporated in the meta-analysis. Figure [1](#Fig1){ref-type="fig"} summarizes the results of the literature search.Figure 1Study flow diagram. BMT, best medical therapy; CAS, carotid stenting; CEA, carotid endarterectomy; RCT, randomised controlled trial.

Description of included studies {#Sec4}
-------------------------------

The characteristics of the selected studies and the specific study population baseline demographics and clinical characteristics are summarised in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively.Table 1Study characteristics.RCTRecruitment periodTotal number of patientsPatient groupsAntiplatelet therapyInclusion criteriaPrimary endpointFollow up**SPACE-2** ^[@CR12]^\
2016\
36 centres Austria, Germany, Switzerland2009--2014513CEA: 203 CAS: 197 BMT: 113CEA: Aspirin CAS: Aspirin + clopidogrel\
BMT: AspirinPatients aged 50--85 years with a 70--99% ICA stenosis based on ultrasound without stroke/TIA symptoms within the preceding 180 daysPrimary safety endpoint: combined rate of death/any stroke within 30 days after CEA or CAS.\
The primary efficacy endpoint: cumulative rate of death/any stroke within 30 days plus the rate of ipsilateral ischemic stroke within 5 years of follow up30 days\
5 years**ACT 1** ^[@CR13]^\
2016\
65 centres\
US2005--20131453CEA: 364 CAS:1089CEA: Aspirin CAS: Aspirin + clopidogrelPatients aged 79 years or younger with 70--99% ICA stenosis without symptoms during the previous 180 days. In the absence of substantial\
(\>60%) contralateral carotid stenosisPrimary end point: 30-day incidence of stroke (Major or minor), death or MI. Or an ipsilateral stroke within 1 year.5 years**Mannheim Trial** ^[@CR14]^\
2016\
Haifa-IsraelNo records136CEA: 68 CAS:68CEA: Aspirin CAS: Aspirin + clopidogrelAsymptomatic (for 6 months) patient with severe carotid atherosclerosis with \>70% ICA stenosisPrimary end point was the 30-day incidence of stroke, death, MI and TIA5 years**AMTEC trial** ^[@CR15]^\
2015\
3 centres\
Russia2009--201455CEA: 31 BMT: 24CEA: Aspirin BMT: AspirinAsymptomatic patient aged \<80, with severe carotid atherosclerosis with 70--79% ICA stenosis, no stroke/TIA in last 6 monthsNonfatal ipsilateral stroke and death from any cause during a follow up period of 5 years.3.3 years**CREST** ^[@CR16]^\
2011\
108 centres US 9 centres Canada2000--20081181CEA: 587 CAS: 594CEA: Aspirin CAS: Aspirin + clopidogrel or ticlopidineICA stenosis of ≥60% on angiography, ≥70% on ultrasound, or ≥80% on CTA/MRA if the stenosis on ultrasonography was 50 to 69%The primary end point: any stroke, myocardial infarction, or death during the periprocedural period or ipsilateral stroke within 4 years30 days\
6 monthly for 4 years**ACST-1** ^[@CR10]^\
2010\
126 centres 30 countries1993--20033120CEA:1560 BMT:1560All patients Aspirin or ClopidogrelAsymptomatic patient (last 6 months) with carotid stenosis of ≥60%The primary endpoint: perioperative mortality and morbidity (death or stroke within 30 days) and non-perioperative stroke.9 years**Kentucky trial** ^[@CR17]^\
2004\
Kentucky US1998--200285CEA: 42 CAS: 43All patients on Aspirin and ClopidogrelAsymptomatic patient with carotid stenosis of more than 80%The primary endpoint: perioperative mortality and morbidity (death or stroke within 30 days)30 days\
4 years\
10 years**SAPPHIRE trial** ^[@CR18]^\
2004\
29 centres US2000--2002237CEA: 120 CAS: 117CEA: Aspirin CAS: Aspirin + clopidogrelAsymptomatic patients with at least 80% ICA stenosis on duplex ultrasonography and at least one coexisting condition that potentially increased the risk posed by carotid endarterectomyThe primary end point: the cumulative incidence of death, stroke, or MI within 30 days after the procedure or death or ipsilateral stroke between 31 days and 1 year.30 days\
1 year\
3 years**ACAS trial** ^[@CR9]^\
1995\
39 centres US/Canada1987--19931659CEA: 825 BMT: 834CEA: Aspirin BMT: AspirinPatients aged 40--79 with asymptomatic ICA stenosis of ≥60%The primary endpoints: TIA, all death/stroke within 30 days after CEA or 42 days in BMT group (to reflect 12 day delay to surgery).\
Efficacy end point: ipsilateral stroke in 5-year period2.7 years**Veterans Affairs trail** ^[@CR19]^\
1993\
11 centres US1983--1987444CEA: 211 BMT: 233CEA: Aspirin BMT: AspirinPatients with asymptomatic ICA stenosis of ≥50%)The primary end point: cumulative incidence of TIA, death, stroke within 30 days after the procedure or death or stroke in 4 years3.9 years**MACE trial** ^[@CR20]^\
1992\
Mayo clinic\
USOver 30 months71CEA: 36 BMT: 35CEA: None\
BMT: AspirinPatients with asymptomatic carotid stenosis (≥50% linear stenosis or 75% cross sectional area stenosis)The primary end point of the trial was the cumulative incidence of TIA, any stroke and death.1.9 yearsBMT, best medical therapy; CAS, carotid stenting; CEA, carotid endarterectomy; CTA, computed tomographic angiography; ICA, internal carotid artery; MI, myocardial infarction; MRA, magnetic resonance angiography; RCT, randomised controlled trial; TIA, transient ischemic attack.Table 2Patient demographic and clinical characteristics.RCTAge (mean+/− SD or range)Male genderHTNCADDMDys-lipidaemiaSmokingCOPDCRFImagingCEAShuntCASCPD**SPACE-2** ^[@CR12]^\
2016\
36 centres Austria, Germany, SwitzerlandCEA: 70 ± 7 CAS: 69 ± 8 BMT:68 ± 7CEA: 74% CAS: 73% BMT:77%CEA: 87% CAS: 90% BMT: 90%CEA: 34% CAS: 37% BMT: 35%CEA: 25% CAS: 30% BMT: 35%CEA: 76% CAS: 80% BMT: 81%Ever Smoked CEA: 66% CAS: 66% BMT: 80%No recordsNo recordsDuplexNo recordsNo recordsNo recordsNo records**ACT 1** ^[@CR13]^\
2016\
65 centres\
USCEA: 67.9 ± 6.9 CAS: 67.7 ± 7.0CEA: 56.9% CAS: 61.2%CEA: 89.6% CAS: 90.6%CEA: 51.1% CAS: 53.4%CEA: 32.4% CAS: 35.6%CEA: 87.9% CAS: 90.0%Ever Smoked CEA: 71.2% CAS: 73.7% Current Smoker CEA: 19.5% CAS: 24.4%CEA: 9.3% CAS: 11.9%CEA: 6.6% CAS: 8.4%Duplex and/or DSANo recordsNo recordsNitinol stentsAll patients**Mannheim Trial** ^[@CR14]^\
2016\
Haifa-IsraelCEA: 68 ± 8 CAS: 69 ± 7CEA: 71% CAS: 66%CEA: 84% CAS: 85%CEA: 50% CAS: 49%CEA: 49% CAS: 47%CEA: 74% CAS: 82%Undefined CEA: 29% CAS: 22%No recordsCEA: 9% CAS: 9%Duplex + CTA or MRARASurgeon preferenceCordis StentAll patients**AMTEC trial** ^[@CR15]^\
2015\
3 centres\
RussiaCEA: 67.0 ± 7.4 BMT: 66.1 ± 6.8CEA: 65% BMT: 83%No records -CEA: 68% BMT: 75%CEA: 29% BMT: 21%No recordsCurrent smoker CEA: 68% BMT: 46%No recordsCEA: 0% BMT: 4%Duplex (NASCET) + CTA or MRAGA Eversion CEA (most Patients)No recordsn/an/a**CREST** ^[@CR16]^\
2011\
108 centres US 9 centres CanadaCEA: 69.6 ± 8.1 CAS: 69 ± 8.0CEA: 67.5% CAS: 63.8%CEA: 87.9% CAS: 88.2%CEA: 26.5% CAS: 23.5%CEA: 33.7% CAS: 32.6%CEA: 91.1% CAS: 89.7%Current smoker CEA: 22.2% CAS: 26.1%No recordsNo recordsDuplex, DSA,CTA,MRAGA: 87.5% Patch: 68.5%53.60%RX Acculink stent96.10%**ACST-1** ^[@CR10]^\
2010\
126 centres 30 countries68 (40--91)65.50%65%No records20%No recordsNo recordsNo recordsNo recordsDuplex (NASCET)Surgeon preferenceOptionaln/an/a**Kentucky trial** ^[@CR17]^\
2004\
Kentucky USCEA: 69.9(48--84) CAS: 66.6(49--85)No recordsCEA: 97.6% CAS: 81.4%CEA: 47.6% CAS: 81.4%CEA: 11.9% CAS: 16.3%CEA: 19.0% CAS: 20.9%Undefined CEA: 88.1% CAS: 93.0%No recordsNo recordsDSAGA all patient with TCDNo recordsWallstent or DynalinkNot used**SAPPHIRE trial** ^[@CR18]^\
2004\
29 centres USCEA: 72.6 ± 8.9 CAS: 72.5 ± 8.3CEA: 67.1% CAS: 66.9%CEA: 85.1% CAS: 85.5%CEA: 75.5% CAS: 85.8%CEA: 27.5% CAS: 25.3%CEA: 76.9% CAS: 78.5%CEA: 16.4% CAS: 16.9%CEA: 13.8% CAS: 17.0%CEA: 7.5% CAS: 6.0%Duplex/DSA for CAS groupNo recordNo recordsNitinol stent (Smart or Precise, Cordis)all patients**ACAS trial** ^[@CR9]^\
1995\
39 centres US/CanadaMean age 67CEA: 66% BMT: 66%CEA: 64% BMT: 64%CEA: 69% BMT: 69%CEA: 25% BMT: 21%No recordsCurrent Smoker CEA: 28% BMT: 24%Lung Disease CEA: 6% BMT: 5%No recordsDSASurgeon preferenceSurgeon preferencen/an/a**Veterans Affairs trail** ^[@CR19]^\
1993\
11 centres USCEA: 64.1 ± 6.8 BMT: 64.7 ± 6.7Only male patientsCEA: 63% BMT: 64%CEA: 30% BMT: 25%CEA: 30% BMT: 27%No recordsCurrent Smoker CEA: 52% BMT: 49% Ever Smoked CEA:95% BMT:91%No recordsNo recordsDSAGASurgeon preferencen/an/a**MACE trial** ^[@CR20]^\
1992\
Mayo clinic\
USCEA \<55: 2.8%\
CEA 55--65: 27.8%\
CEA \>65: 69.% BMT \<55: 5.7%\
BMT 55--65: 22.9%\
BMT \>65: 71.4%CEA: 55.6% BMT: 60%CEA: 63.9% BMT: 62.9%CEA: 41.7% BMT: 40%CEA: 19.4% BMT: 14.3%CEA: 44.4% BMT: 65.7%Current Smoker CEA: 25% BMT: 31.4% Ever Smoked CEA:66.7% BMT:74.3%No recordsNo recordsDuplex/DSA/ocular pneumo-plethys-mographyNo recordsNo recordsn/an/aBMT, best medical therapy; CAD, coronary artery disease; CAS, carotid stenting; CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease; CPD, cerebral protection device; CRF, chronic renal failure; CTA, computed tomographic angiography; DM, diabetes mellitus; DSA, digital subtraction angiography; GA, general anaesthetic; HTN, hypertension; ICA, internal carotid artery; MI, myocardial infarction; MRA, magnetic resonance angiography; RA, regional anaesthetic; RCT, randomised controlled trial; SD, standard deviation; TCD, transcranial doppler; TIA, transient ischemic attack.

### CEA vs. CAS vs. BMT {#Sec5}

SPACE-2^[@CR12]^ is the only RCT that was planned as a three-armed trial, namely BMT alone vs. CEA plus BMT vs. CAS plus BMT. This trial was powered to randomize more than 3000 patients over a 5-year period. Because of slow patient recruitment, the three-arm study design was amended in July 2013 to become two parallel randomized studies (BMT alone vs. CEA plus BMT and BMT alone vs. CAS plus BMT). However, again due to slow recruitment, the trial was ceased after enrolment of 513 patients over a 5-year period (CEA plus BMT, n = 203; CAS plus BMT, n = 197; and BMT alone, n = 113). Patients were followed up for up to five years to produce long-term primary efficacy data.

### CEA vs. BMT {#Sec6}

We identified five RCTs^[@CR9],[@CR10],[@CR15],[@CR19],[@CR20]^ reporting comparative outcomes of CEA vs. BMT for asymptomatic carotid disease, which were published between 1992 and 2015. The overall study population comprised of 5349 patients, 2663 in the CEA group and 2686 in the BMT group. Single antiplatelet therapy in the form of aspirin was used in both treatment groups in all but one trial^[@CR20]^, in which CEA patients received no antiplatelet therapy. BMT as per current guidelines were used in only one trial^[@CR15]^, the remaining trail did not provide elements of their BMT protocol. In ACST 1^[@CR10]^ the use of lipid lowering drugs improved significantly during the study period (initially only 7% and at the end of the trail 82%). Follow up ranged between two and ten years. There were no significant differences in baseline demographics and clinical characteristics between the CEA and BMT groups.

### CEA vs. CAS {#Sec7}

We identified five RCTs^[@CR13],[@CR14],[@CR16]--[@CR18]^ reporting comparative outcomes of CEA vs. CAS for asymptomatic carotid disease, which were published between 2008 and 2016. The studies included a total of 3092 patients; 1181 of them underwent CEA and the remaining 1911 underwent CAS. Patients in the CEA group received single antiplatelet therapy with aspirin, whereas those undergoing CAS received dual antiplatelet therapy (aspirin and clopidogrel). Follow up ranged from three to ten years. There were no significant differences in baseline demographics and clinical characteristics between the CEA and BMT groups.

Risk of bias assessment {#Sec8}
-----------------------

Random sequence generation and allocation concealment methods were adequately described in all but one trial^[@CR14]^, which did not state patient selection methods. Due to the nature of intervention, blinding of participants and personnel was not possible resulting in a high risk of performance bias. In six RCTs^[@CR9],[@CR10],[@CR12],[@CR18]--[@CR20]^, blinding of outcome assessors was adequately described, whereas in the remaining trials, this parameter was inadequately reported. Five RCTs^[@CR12],[@CR13],[@CR15],[@CR18],[@CR20]^ were found to have incomplete outcome data (attrition bias). Four RCTs^[@CR12],[@CR13],[@CR15],[@CR18]^ were terminated early, three due to slow enrolment and one due to an unacceptable complication rate in the CEA group^[@CR20]^. No reporting bias was identified in any of the trials. The risk of bias assessment of the RCTs is summarised in Fig. [2](#Fig2){ref-type="fig"}.Figure 2(**a**) Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. (**b**) Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Effects of interventions {#Sec9}
------------------------

### Pair-wise meta-analysis {#Sec10}

Forest plots of comparisons of CEA vs. BMT and CEA versus CAS are presented in Figs [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}, respectively.Figure 3Forest plots of comparisons of CEA vs. BMT). The solid squares denote the odds ratios (ORs) or risk difference (RD). The horizontal lines represent the 95% confidence intervals (CIs), and the diamond denotes the pooled effect size. BMT, best medical therapy; CEA, carotid endarterectomy; M-H, Mantel Haenszel test; MI, myocardial infarction; TIA, transient ischaemic attack.Figure 4Forest plots of comparisons of CEA vs. CAS. The solid squares denote the odds ratios (ORs) or risk difference (RD). The horizontal lines represent the 95% confidence intervals (CIs), and the diamond denotes the pooled effect size. CAS, carotid stenting; CEA, carotid endarterectomy; M-H, Mantel Haenszel test; MI, myocardial infarction; TIA, transient ischaemic attack.

### CEA vs. BMT {#Sec11}

*Thirty-day ipsilateral stroke*. Data on 30-day ipsilateral stroke were reported in all five studies^[@CR9],[@CR10],[@CR15],[@CR19],[@CR20]^. In the CEA group (2835 patients), the incidence of 30-day ipsilateral stroke was 1.6%, whereas in the BMT group (2775 patients), the incidence was 0.4% (RD: 0.01, 95% CI: 0.01--0.02, P \< 0.00001). We found no evidence of heterogeneity among the studies (I^2^ = 0%, P = 0.44). Excluding trials that were judged to be at high risk of bias in two or more domains (ACAS^[@CR9]^, ACST-1^[@CR10]^, SPACE-2^[@CR12]^) showed no difference between the treatment groups (RD: 0.02, 95% CI: −0.00--0.04, P = 0.11). The recruitment period started after 2000 in one trial only (SPACE-2 trial^[@CR12]^), which found no significant difference in 30-day stroke risk between treatments (OR: 5.12, 95% CI: 0.27--95.97, P = 0.27). The GRADE level of evidence for this outcome was judged to be high.

*Thirty-day mortality*. Data on 30-day mortality were reported in all five studies^[@CR9],[@CR10],[@CR15],[@CR19],[@CR20]^. The 30-day mortality rate was 0.8% in the CEA group (2853 patients) and 0.1% in the BMT group (2775 patients) (RD: 0.01, 95% CI: 0.00--0.01, P = 0.0006). The likelihood of between-study heterogeneity was low (I^2^ = 18%, P = 0.3). Excluding trials that were judged to be at high risk of bias in two or more domains (ACAS^[@CR9]^, ACST-1^[@CR10]^, SPACE-2^[@CR12]^) showed no difference between the treatment groups (RD: 0.01, 95% CI: −0.01--0.03, P = 0.19). The recruitment period started after 2000 in one trial only (SPACE-2 trial^[@CR12]^), which reported no mortality within 30 days in either group. The GRADE level of evidence for this outcome was judged to be high.

*Thirty-day ipsilateral minor stroke/TIA*. Data on 30-day minor stroke/TIA were reported in three trials^[@CR10],[@CR19],[@CR20]^. In the CEA group (1807 patients), the incidence of minor stroke/TIA at 30-days was 1.2%, while in the BMT group (1828 patients), the incidence was 0.7% (OR: 1.63, 95% CI: 0.81--3.27, P = 0.17). There was no evidence of significant statistical heterogeneity among the studies (I^2^ = 46%, P = 0.16). Excluding the trial that was judged to be at high risk of bias in two or more domains (ACST-1^[@CR10]^) showed no difference between the treatment groups (OR: 0.61, 95% CI: 0.14--2.55, P = 0.5). The recruitment period started before 2000 in all trials included in the analysis. The GRADE level of evidence for this outcome was judged to be high.

*Thirty-day MI*. Data on 30-day MI were reported in three studies^[@CR10],[@CR19],[@CR20]^. In the CEA group (1807 patients), MI within 30 days of treatment occurred in 1.2% of patients, whereas in the BMT group (1828 patients), MI within 30 days occurred in 0.1% (OR: 12.07, 95% CI: 2.82--51.6, P = 0.0008). There was no evidence of statistical heterogeneity among the studies (I^2^ = 0%, P = 0.92). Excluding the trial that was judged to be at high risk of bias in two or more domains (ACST-1^[@CR10]^) showed a difference in favour of BMT (OR: 8.78, 95% CI: 1.08--71.21, P = 0.04). The recruitment period started before 2000 in all trials included in the analysis. The GRADE level of evidence for this outcome was judged to be high.

*Ipsilateral stroke during follow up*. Data on ipsilateral stroke during follow up were reported in four studies^[@CR9],[@CR10],[@CR15],[@CR19]^. In the CEA group (2627 patients), the incidence of stroke was 8.4%, whereas in the BMT group (2651 patients), ipsilateral stroke occurred in 13.4% of patients (OR: 0.59, 95% CI: 0.49--0.7, P \< 0.00001). We found no evidence of statistical heterogeneity among the selected studies (I^2^ = 0%, P = 0.49). Excluding trials that were judged to be at high risk of bias in two or more domains (ACAS^[@CR9]^, ACST-1^[@CR10]^, AMTEC^[@CR15]^) showed no difference between the treatment groups (OR: 0.48, 95% CI: 0.22--1.03, P = 0.06). Only one trial (ACST-1^[@CR10]^) provided follow-up data \>5 years; it found a significance difference in stroke risk in favour of CEA (OR: 0.59, 95% CI: 0.48--0.73, P \< 0.00001). The recruitment period started after 2000 in one trial only (AMTEC^[@CR15]^), which found no significant difference in the follow-up stroke risk between treatments (OR: 0.13, 95% CI: 0.01--1.17, P = 0.07). The GRADE level of evidence for this outcome was judged to be high.

*Mortality during follow up*. Data on long-term mortality were reported in three studies^[@CR9],[@CR10],[@CR15]^. The mortality rate during follow up was 5.1% in the CEA group (2416 patients) and 6.6% in the BMT group (2418 patients) (OR: 0.75, 95% CI: 0.59--0.96, P = 0.02). We found no evidence of significant statistical heterogeneity among the studies (I^2^ = 64%, P = 0.06). All three trials included in this analysis were at high risk of bias in two or more domains. Only one trial (ACST-1^[@CR10]^) provided follow-up data \>5 years; it found a significance difference in mortality in favour of CEA (OR: 0.56, 95% CI: 0.38--0.84, P = 0.005). The recruitment period started after 2000 in one trial only (AMTEC^[@CR15]^), which found no significant difference in mortality risk during follow up between treatments (OR: 0.17, 95% CI: 0.02--1.6, P = 0.12). The GRADE level of evidence for this outcome was judged to be high.

*Ipsilateral minor stroke/TIA during follow up*. Data on long-term ipsilateral minor stroke/TIA were reported in two trials^[@CR19],[@CR20]^. During follow up, ipsilateral minor stroke/TIA occurred in 3.2% in the CEA group (247 patients) and in 1.9% in the BMT group (268 patients) (OR: 0.27, 95% CI, 0.12--0.59, P = 0.001). We identified no evidence of statistical heterogeneity (I^2^ = 0%, P = 0.86). Both trials were found to be of risk of bias in less than two domains. Neither reported follow up \>5 years. The recruitment period started before 2000 in both trials included in the analysis. The GRADE level of evidence for this outcome was judged to be high.

*MI during follow up*. Data on MI during follow up were reported in two studies^[@CR15],[@CR20]^. MI during the follow-up period occurred in one patient (1.5%) in the CEA group (67 patients) and in two patients (3.3%) in the BMT group (59 patients) (OR: 0.57, 95% CI: 0.1--3.38, P = 0.54). There was no evidence of statistical heterogeneity between the two studies (I^2^ = 44%, P = 0.18). One trial (AMTEC^[@CR15]^) was judged to be of high risk of bias in more than two domains; excluding this trial revealed no difference in the risk of MI during follow up between treatment groups (OR: 3, 95% CI: 0.12--76.16, P = 0.51). None of the trials reported follow up \>5 years. The recruitment period started after 2000 in one trial only (AMTEC^[@CR15]^), which found no significant difference in mortality risk during follow up (OR: 0.14, 95% CI: 0.01--3.12, P = 0.22). The GRADE level of evidence for this outcome was judged to be high.

### CEA vs. CAS {#Sec12}

*Thirty-day ipsilateral stroke*. Data on ipsilateral stroke within 30 days of treatment were reported in all five studies^[@CR13],[@CR14],[@CR16]--[@CR18]^. The 30-day incidence of ipsilateral stroke was 1% in the CEA group (1264 patients) and 1.2% in the CAS group (1991 patients) (RD: −0.01, 95% CI: −0.01--0.00, P = 0.16). There was no evidence of statistical heterogeneity among the studies (I^2^ = 0%, P = 0.56). All trials were judged to be at high risk of bias in two or more domains. The recruitment period started before 2000 in one trial (Kentucky);^[@CR17]^ excluding this trial from the analysis showed no difference in the stroke risk within 30 days between CEA and CAS (RD: −0.01, 95% CI: −0.01--0.00, P = 0.15). The GRADE level of evidence for this outcome was judged to be moderate.

*Thirty-day mortality*. Data on 30-day mortality were reported in all five trials^[@CR13],[@CR14],[@CR16]--[@CR18]^. Mortality was 0.7% in the CEA group (1264 patients) and 0.8% in the CAS group (1991 patients) (RD: −0.00, 95% CI: −0.01--0.00, P = 0.27). We found no evidence of statistical heterogeneity (I^2^ = 31%, P = 0.21). All trials were judged to be at high risk of bias in two or more domains. Excluding the trial where the recruitment period started before 2000 (Kentucky)^[@CR17]^ revealed no difference in the 30-day mortality risk between CEA and CAS (RD: −0.00, 95% CI: −0.01--0.00, P = 0.26). The GRADE level of evidence for this outcome was judged to be moderate.

*Thirty-day ipsilateral minor stroke/TIA*. Data on ipsilateral minor stroke/TIA occurring within 30 days of treatment were reported in three trials^[@CR13],[@CR14],[@CR17]^. In the CEA group (474 patients), the 30-day incidence of minor stroke/TIA was 1.1%, while in the CAS group (1200 patients), it was 1.9% (RD: −0.01, 95% CI: −0.02--0.01, P = 0.23). We found no significant between-study heterogeneity (I^2^ = 0%, P = 0.86). All three trials were judged to be at high risk of bias in two or more domains. Excluding the trial with recruitment starting before 2000 (Kentucky)^[@CR17]^ revealed no difference in the risk of minor stroke/TIA (RD: −0.01, 95% CI: −0.02--0.00, P = 0.21). The GRADE level of evidence for this outcome was judged to be moderate.

*Thirty-day MI*. Data on MI within 30 days of treatment were reported in three studies^[@CR13],[@CR14],[@CR16]^. In the CEA group (1019 patients), MI occurred in 1.6% of patients, whereas in the CAS group (1751 patients), MI within 30 days of treatment occurred in 0.7% (RD: 0.01, 95% CI: −0.00--0.02, P = 0.13). The statistical heterogeneity was insignificant (I^2^ = 0%, P = 0.67). All trials were judged to be at high risk of bias in two or more domains, and their recruitment period started after 2000. The GRADE level of evidence for this outcome was judged to be moderate.

*Ipsilateral stroke during follow up*. Data on long-term ipsilateral stroke were reported in two studies^[@CR13],[@CR18]^. The stroke rate was 4.3% in the CEA group (484 patients) and 3% in the CAS group (1206 patients) (OR: 1.05, 95% CI: 0.59--1.87, P = 0.86). The statistical heterogeneity was low (I^2^ = 0%, P = 0.8). Both trials were judged to be at high risk of bias in two or more domains. None of the trials selected for analysis reported follow up longer than five years. Both trials started recruitment after 2000. The GRADE level of evidence for this outcome was judged to be moderate.

*Mortality during follow up*. Data on long-term mortality were reported in two studies^[@CR13],[@CR14]^. In the CEA group (432 patients), long-term mortality was 9.5%, and in the CAS group (1157 patients), it was 12.3% (OR: 0.79, 95% CI: 0.55--1.15, P = 0.22). There was no significant between-study heterogeneity (I^2^ = 0%, P = 0.74). Both trials were judged to be at high risk of bias in two or more domains. None of the trials selected for analysis reported follow up longer than five years. Both trials started recruitment after 2000. The GRADE level of evidence for this outcome was judged to be moderate.

*Ipsilateral minor stroke/TIA during follow up*. Data on long-term ipsilateral minor stroke/TIA were reported in one trial^[@CR14]^. In the CEA group (68 patients), no minor ipsilateral stroke/TIA occurred during follow up, and in the CAS group (68 patients), one patient developed a TIA during the follow-up period (1.5%) (OR: 0.33, 95% CI: 0.01--8.21, P = 0.5). The GRADE level of evidence for this outcome was judged to be low.

*MI during follow up*. No data on MI during follow up were reported in the selected trials.

### CAS vs. BMT {#Sec13}

There was no RCT comparing clinical outcomes between CAS and BMT.

### Network meta-analysis {#Sec14}

The geometry of the network of interventions for the primary outcomes yielded an open network without closed loops, as only the SPACE-2^[@CR12]^ trial included all three treatment groups, reporting 30-day outcome data only. This has led to limited diversity. Excluding the SPACE-2 trial^[@CR12]^, each comparison is represented only by indirect comparisons (CEA vs BMT or CEA vs CAS); no trial provided direct evidence between CAS and BMT.

All but two studies^[@CR15],[@CR18]^ reported 30-day mortality data. Considering BMT as the reference treatment, ORs and 95% CIs for 30-day mortality were as follows: CAS, 8.41 (2.16--32.71) and CEA, 5.42 (1.85--15.95) with the result favouring BMT (Table [3](#Tab3){ref-type="table"}). For this outcome parameter, the probability of BMT to be the best treatment was 99.9%.Table 3Network meta-analyses league table.BMTCASCEA30-day mortalityBMT*99.9 (99.8%)***0.12 (0.03, 0.46)0.18 (0.06, 0.54)**CAS**8.41 (2.16, 32.71)***7.7 (0.2%)*1.55 (0.68, 3.54)CEA**5.42 (1.85, 15.95)**0.65 (0.28, 1.47)*42.4 (0.0%)*Long-term mortalityBMT*20.1(5.8%)*1.19 (0.54, 2.61)1.43 (0.89, 2.30)CAS0.84 (0.38, 1.84)*47.6 (27.6%)*1.20 (0.65, 2.21)CEA0.70 (0.43, 1.12)0.83 (0.45, 1.53)*82.3 (66.6%)*30-day ipsilateral strokeBMT*100 (100%)***0.15 (0.06, 0.39**)**0.24 (0.12, 0.48)**CAS**6.83 (2.60, 17.97)***4.3 (0%)*1.65 (0.81, 3.34)CEA**4.15 (2.09, 8.22)**0.61 (0.30, 1.23)*45.7 (0%)*Long-term ipsilateral strokeBMT*1.8 (0%)*1.73 (0.95, 3.15)**1.69 (1.41, 2.02)**CAS0.58 (0.32, 1.05)*75.0 (53.6%)*0.97 (0.55, 1.72)CEA**0.59 (0.50, 0.71)**1.03 (0.58, 1.82)*73.2 (46.4%)*30-day myocardial infarctionBMT*79.9 (60.7%)*0.69 (0.05, 9.94)**0.09 (0.01, 0.65)**CAS1.45 (0.10, 20.77)*69.0 (39.3%)***0.13 (0.02, 0.79)**CEA11.04 (1.53, 79.53)7.64 (1.27, 46.04)*1.2 (0.0%)*30-day ipsilateral minor stroke/TIABMT*87.5 (76.4%)***0.42 (0.19, 0.93)**0.66 (0.21, 2.08)CAS**2.37 (1.07, 5.26)***9.5 (22.3%)*1.56 (0.62, 3.97)CEA1.52 (0.48, 4.77)0.64 (0.25, 1.62)*52.9 (1.3%)*Long-term ipsilateral minor stroke/TIABMT*24.3 (0.2%)*1.08 (0.04, 29.89)**3.29 (1.45, 7.46)**CAS0.93 (0.03, 25.64)*38.5 (48.1%)*3.04 (0.01, 8.21)CEA**0.30 (0.13, 0.69)**0.33 (0.01, 8.21)*87.2 (51.7%)*Estimates are presented as odds ratio (OR) with 95% confidence interval (CI) in parentheses. ORs above 1 suggest that the treatment listed in the upper row is superior; ORs below 1 suggest that the treatment listed in the left column is superior. Surface under the cumulative ranking curve values (SUCRAs) are given in the diagonal and the probability of being the best treatment in parentheses. Statistically significant values are given in bold. BMT, best medical therapy; CAS, carotid stenting; CEA, carotid endarterectomy; TIA, transient ischaemic attack.

Five trials provided data on long-term mortality^[@CR9],[@CR10],[@CR13]--[@CR15]^. With CEA as the reference, ORs and 95% CIs for long-term mortality were as follows: BMT, 1.43 (0.89--2.30) and CAS, 1.20 (0.65--2.21), with the result favouring CEA without reaching statistical significance (Table [3](#Tab3){ref-type="table"}). For long-term mortality, the probabilities of CEA, CAS and BMT to be the best treatment were 66.6%, 27.6% and 5.8% respectively.

All but one trial^[@CR15]^ reported data on 30-day ipsilateral stroke. With BMT as reference treatment, ORs and 95% CIs for 30-day ipsilateral stroke were as follows: CAS, 2.37(1.07--5.26) and CEA, 1.52(0.48--4.77), with the result favouring BMT (Table [3](#Tab3){ref-type="table"}). For this outcome, the probability of BMT to be the best treatment was 100%.

Six trials provided data on long-term ipsilateral stroke^[@CR9],[@CR10],[@CR13],[@CR15],[@CR18],[@CR19]^. With CEA as the reference, ORs and 95% CIs for long-term ipsilateral stroke were as follows: BMT, 1.69 (1.41--2.02) and CAS, 0.97 (0.55--1.72), with statistically significant results in favour of CEA over BMT only (Table [3](#Tab3){ref-type="table"}). For ipsilateral stroke during follow up, the probabilities of CEA, CAS and BMT to be the best treatment were 46.4%, 53.6% and 0%, respectively.

The results from network meta-analysis predictive interval showed that future trails are highly likely to change the direction of the treatment effect for patients with asymptomatic carotid disease, particularly so for BMT.

Discussion {#Sec15}
==========

We conducted a pairwise and network meta-analysis of treatment strategies for asymptomatic carotid disease including a total of 8954 patients from 11 randomised clinical trials. Pairwise treatment meta-analysis showed that CEA is superior to BMT in reducing the risk of long-term mortality and stroke. There were no statistical significant differences between CEA and CAS in terms of peri-interventional or long term ipsilateral stoke/mortality.

The value of CEA in reducing the risk of stroke in asymptomatic carotid artery stenosis is predominantly based on two seminal studies performed in the 1990s. The ACAS^[@CR9]^ was a well-conducted RCT that was halted at 2.7 years because of a projected 5.9% absolute risk reduction at five years favouring CEA. BMT in this trail were only in the form of Aspirin and a general discussion in cardiovascular risk reduction factors. The ACST trial^[@CR10]^ randomized 3120 asymptomatic carotid artery stenosis patients to immediate CEA or delayed surgery for symptoms only. Combining perioperative events and strokes, net risks were 6.9% vs. 10.9% at 5 years and 13.4% vs. 17.9% at 10 years.BMT improved significantly during these ten years with 82% of patient on lipid lowering by drugs by the end of trail compare to only 7% at the beginning of the trail.

In 2016, the results from two large RCTs comparing CEA with CAS in asymptomatic carotid stenosis patient were published. The CREST trial^[@CR21]^ and ACT 1^[@CR13]^ resolved the durability dilemma with CAS. However, these trials did not resolve the issue of generalisability of these findings into routine clinical practice, where rates of death and stroke may be much higher among patients undergoing carotid stenting^[@CR22]^.

In CEA vs. BMT, the quality of the evidence was judged to be high according to the GRADE system. This was reduced to moderate/low for CEA vs. CAS as all trials included in the analysis were judged to be at high risk of bias in two or more domains.

Systematic review^[@CR23]^ of 47 studies (6 RCTs and 41 observational studies) investigating the evidence on management strategies for asymptomatic carotid stenosis also concluded that the evidence was not sufficiently robust or applicable to current clinical practice to allow clinicians to draw confident conclusions on the comparative effectiveness of management strategies for adults with asymptomatic carotid stenosis. Moresoli *et al*.^[@CR24]^, published a meta-analysis of 11 studies (5 RCTs and 6 observational studies) on CAS vs CEA in asymptomatic carotid disease. The results of this meta-analysis corroborate our findings as there was no clinically significant differences between treatments for long-term stroke (RR, 1.24; 95% CI, 0.76--2.03) and the composite outcome of periprocedural stroke, death or MI, or long-term ipsilateral stroke (RR, 0.92; 95% CI, 0.70--1.21). Most recently, Kakkos SK *et al*.^[@CR25]^ published a meta-analysis of 9 RCTs comparing CEA with CAS in asymptomatic carotid disease patients. Regarding the long-term outcome of stroke or death rate at 30 days plus ipsilateral stroke during follow-up, this was significantly higher for CAS (3.64%) than for CEA (2.45%) (OR, 1.51; 95% CI, 1.02--2.24; P = 0.04; I2 = 0%). However, quality of evidence for all stroke outcomes was graded moderate.

The network meta-analysis is the first to be undertaken in this area. It demonstrates that CAS and CEA increase the risk of death and ipsilateral stroke at 30 days compared to BMT. This is an unsurprising finding given the well reported risks of revascularisation interventions. The network meta-analysis results favour CEA in the long term, but this finding is less conclusive.

CREST-2^[@CR26]^ and ACST-2^[@CR27]^ trials are currently running to provide level 1 evidence in regards of treatment strategy for asymptomatic carotid artery disease. CREST-2 consists of 2 parallel, RCTs. One trial will compare BMT to CEA BMT. The parallel trial will compare BMT to CAS plus BMT. An estimated 2480 participants will be enrolled in CREST-2 at approximately 120 sites in the United States and in several Canadian sites. ACST-2 is a large international RCT comparing CEA versus CAS in patients with asymptomatic carotid stenosis. ACST-2 is currently recruiting patients from over 112 centres in over 20 countries worldwide. The trial is on track to recruit 3600 patients by 2019.

The results of our review should be interpreted with caution in view of the following limitations. The two major limitations to the pair-wise meta-analysis are variation in follow up period together with significant heterogeneity in BMT within and between the studies. Follow up period were between 30-days and 9 years. This variation will have an effect in reporting outcome measures using OR. This is particularly true when event rate is low, as in carotid trials. In terms of BMT, only one trail^[@CR15]^ adhered to current guidelines of aggressive medical therapy (blood pressure control, DM treatment, lipid lowering agents) together with lifestyle modification (exercise, smoking cessation and weight reduction). Antiplatelet were the only components of BMT in earlier trails with introduction to statin treatment in late 90s. No sufficient data are provided by the randomised clinical trials included in our review to allow us to perform meta-regression analysis to investigate the effect of statin and/or aspirin on the outcomes. In addition, within CEA/CAS trial patients received different BMT regime (dual antiplatelet treatment if were allocated to CAS). However we tried to overcome these limitations by conducting sensitivity analysis excluding old studies and those with \<5 years follow up.

There were also limitations in the NMA. The network geometry did not provide any closed loops across the competing interventions except for one trial that provided data on 30-day ipsilateral stroke only; therefore, we were not able to assess inconsistency between direct and indirect evidence. There was no direct comparison between CAS and BMT. There was a different time span between trials comparing CEA vs. BMT (1997--2015) and CEA vs. CAS (2004--2016), which might challenge transitivity (assumption of similarity in the study characteristics between trails). Transitivity might be also challenged by the variation in the components of BMT and variation in the inclusion criteria. Similarly, the difference in follow up across trials and across the network may introduce heterogeneity and inconsistency, respectively.

Conclusions {#Sec16}
===========

Surgical intervention with CEA is superior to BMT in preventing long term ipsilateral stroke/mortality in asymptomatic carotid disease, but there is probably no difference between CEA and CAS. CREST-2 will clarify whether revascularization interventions provide long-term benefit to patients treated by current best-available medical therapy.

Methods {#Sec17}
=======

Design {#Sec18}
------

This systematic review followed the guidelines of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions^[@CR28]^. The International Prospective Register of Systematic Reviews (PROSPERO) registration number of this protocol is CRD 42016046153.

Criteria for considering studies for this review {#Sec19}
------------------------------------------------

### Types of studies {#Sec20}

Only randomised controlled trials (RCTs) investigating the outcomes of CEA, CAS and BMT in asymptomatic carotid disease were considered in this review.

### Types of participants {#Sec21}

We included any patients (no age or gender restriction) diagnosed with carotid stenosis \>50% without any neurological symptoms indicating a cerebrovascular event during the 180 days preceding initiation of treatment for carotid disease. The diagnosis of carotid disease should have been established with objective diagnostic measures, e.g. duplex ultrasonography, magnetic resonance (MR) angiography, digital subtraction angiography (DSA), or computed tomographic (CT) angiography.

### Types of interventions {#Sec22}

We planned to compare outcomes of patients with asymptomatic carotid disease undergoing treatment with CEA, CAS and BMT. CEA could have been performed under general or local anaesthesia. Any technique of CEA was considered including conventional endarterectomy with direct or patch closure or the eversion technique. CAS could have been performed with or without a cerebral protective device (CPD). We considered any type of stent including a closed or open cell design. BMT was implemented according to evidence-based guidelines; it mainly consisted of optimal antiplatelet therapy according to clinical practice at the participating centres, cholesterol-lowering agents (e.g. statin), antihypertensive medication and targeted risk factor modification.

### Types of outcome measures {#Sec23}

*Primary outcomes* Death and stroke occurring within 30 days of treatment or during the hospital stay for the index procedure (CEA or CAS) and during follow up.*Secondary outcomes*Myocardial infarction (MI) occurring in the perioperative period (within 30 days or during the hospital stay) and during follow up.Transient ischemic attack (TIA) occurring in the perioperative period (within 30 days or during the hospital stay) and during follow up.

Search methods for identification of studies {#Sec24}
--------------------------------------------

The literature search strategy was developed in consultation with a clinical information specialist. Eligible studies were identified by searching Cochrane Central Register of Controlled Trials (CENTRAL), Excerpta Medica database (EMBASE), U.S. National Library of Medicine's database (MEDLINE), Cumulative Index to Nursing and Allied Health Literature (CINAHL). World Health Organization (WHO) International Clinical Trials Registry and the ISRCTN Register was searched for on-going clinical trials. The final search was carried out in October 2016. The search was not restricted to any language. The literature search strategy is presented in Appendix I.

Data extraction and management {#Sec25}
------------------------------

Two review authors (MB, IR) independently evaluated the studies and selected the studied that fulfilled the inclusion criteria for this review. A third author (GAA) then assess all the selected studie and ensure their eligibility for the inclusion criteria and also acted as an adjudicator in the event of disagreement.

We developed a data extraction sheet, which was pilot-tested and refined accordingly. One review author (MB) extracted the data from the selected studies and a second review author (IR) crosschecked the collected data. Disagreements were resolved by discussion between the authors. The following data were collected:Study-related information (first author, year of publication, single-centre or multi-centre study).Baseline demographics and clinical characteristics of the study populations (age, gender, diabetes mellitus, hypertension, type of carotid intervention, type of antiplatelet therapy).Outcome data, as outlined above.

Assessment of risk of bias in included studies {#Sec26}
----------------------------------------------

We applied the Cochrane tool for the assessment of the risk of bias of the selected trials^[@CR29]^. Briefly, this tool evaluates six main domains: random sequence generation and allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. For each individual domain, we classified studies into low, unclear, or high risk of bias.

The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) working group system was utilised for grading the quality of evidence as high, moderate, low and very low, based on directness of evidence, within-study risk of bias, precision of effects estimates, heterogeneity, and risk of publication bias^[@CR30]^.

Methods of analysis {#Sec27}
-------------------

We used the RevMan 5.3 software (Cochrane collaboration, Copenhagen, Denmark) for pair-wise meta-analyses. Treatment effect estimates were calculated using the odds ratio (OR) or risk difference (RD) and 95% confidence interval (CI) to reflect the uncertainty of point estimate of effects. We based calculations using an intention-to-treat approach and all randomized participants were included in the analysis regardless of loss to follow up. The unit of analysis was the individual patient. For data synthesis, we used a fixed-effect model to calculate the pooled treatment effect and 95% CI for dichotomous outcome variables. We used a random-effects model when we found significant heterogeneity (defined as I^2^ greater than 75%). We created a forest plot for each treatment effect.

We assessed inter-study heterogeneity visually using a forest plot. We also calculated the I^2^ statistic to measure the amount of interstudy heterogeneity. We considered I^2^ values less than 50% as indicative of low heterogeneity, I^2^ values between 50% and 75% as indicative of moderate heterogeneity, and I^2^ values greater than 75% as indicative of significant heterogeneity.

We planned to construct a funnel plot to test for reporting bias in meta-analyses that included 10 or more studies. We planned to assess publication bias visually evaluating the symmetry of the funnel plots. We also planned to mathematically estimate publication bias using the Egger's regression intercept.

We performed sensitivity analysis by sequentially excluding trials with a high risk of bias in two or more domains and performed a pooled sensitivity analysis in order to assess whether the included studies, deemed to be biased, impacted the final analysis. We also performed separate analysis of follow-up outcome data for studies providing follow up longer than five years. We performed sensitivity analysis excluding old studies (where the recruitment period started before 2000).

We performed a network meta-analysis in Stata version 13 (College Station, Texas, USA) using the *network* command and self-programmed Stata routines^[@CR31]--[@CR33]^. We used the restricted maximum likelihood method to estimate heterogeneity assuming a common estimate for the heterogeneity variance across the different comparisons. We estimated the ranking probabilities for all treatments of being at each possible rank for each intervention. We obtained a hierarchy of the competing interventions using rankograms and the surface under the cumulative ranking curve (SUCRA) and mean ranks^[@CR34]^. We produced the relevant plots using the suite of Stata commands by Chaimani *et al*.^[@CR33]^.

Data availability {#Sec28}
-----------------

The data spread sheet generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
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